| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
44,800,000 |
| Market
Cap: |
168.90(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$1.4 - $9.48 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Kodiak Sciences is a biopharmaceutical company focused on researching, developing and commercializing therapeutics to treat high prevalence retinal diseases. Co.'s Antibody Biopolymer Conjugate Platform™ uses molecular engineering to merge the fields of antibody-based and chemistry-based therapies. Co.'s main product candidate, KSI-301, is an anti-vascular endothelial growth factor antibody biopolymer conjugate for the treatment in retinal vascular diseases including wet age-related macular degeneration (AMD), diabetic macular edema and retinal vein occlusion. Co.'s pipeline, including product candidates KSI-501 and KSI-601, are used for other needs in retina such as dry AMD and glaucoma.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
1,379,445 |
| Total Buy Value |
$0 |
$0 |
$0 |
$9,508,745 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
9 |
| Total Shares Sold |
0 |
0 |
7,587 |
15,417 |
| Total Sell Value |
$0 |
$0 |
$70,517 |
$126,006 |
| Total People Sold |
0 |
0 |
2 |
2 |
| Total Sell Transactions |
0 |
0 |
4 |
8 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Ehrlich Jason |
See Remarks |
• – – |
2020-05-20 |
4 |
OE |
$10.29 |
$71,516 |
D/D |
6,950 |
38,234 |
|
- |
|
| Ehrlich Jason |
See Remarks |
• – – |
2020-04-20 |
4 |
AS |
$52.44 |
$376,115 |
D/D |
(6,950) |
31,284 |
|
-5% |
|
| Ehrlich Jason |
See Remarks |
• – – |
2020-04-20 |
4 |
OE |
$10.29 |
$71,516 |
D/D |
6,950 |
38,234 |
|
- |
|
| Ehrlich Jason |
See Remarks |
• – – |
2020-04-09 |
4 |
AS |
$47.54 |
$106,830 |
D/D |
(2,200) |
31,284 |
|
-7% |
|
| Ehrlich Jason |
See Remarks |
• – – |
2020-04-09 |
4 |
D |
$50.67 |
$205,619 |
D/D |
(4,058) |
33,484 |
|
- |
|
| Ehrlich Jason |
See Remarks |
• – – |
2020-04-09 |
4 |
OE |
$0.00 |
$0 |
D/D |
15,000 |
37,542 |
|
- |
|
| Bancroft Charles A |
Director |
– • – |
2020-04-02 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
25,948 |
|
11% |
|
| Liang Hong |
SVP, Discovery Medicine |
• – – |
2020-04-02 |
4 |
AS |
$42.34 |
$169,360 |
D/D |
(4,000) |
130,166 |
|
11% |
|
| Liang Hong |
SVP, Discovery Medicine |
• – – |
2020-03-26 |
4 |
AS |
$47.28 |
$191,112 |
D/D |
(4,000) |
134,166 |
|
-4% |
|
| Levy Richard S |
Director |
– • – |
2020-03-20 |
4 |
B |
$43.37 |
$44,330 |
D/D |
1,000 |
1,000 |
2.39 |
11% |
|
| Ehrlich Jason |
See Remarks |
• – – |
2020-03-20 |
4 |
AS |
$42.32 |
$312,762 |
D/D |
(6,950) |
22,542 |
|
11% |
|
| Ehrlich Jason |
See Remarks |
• – – |
2020-03-20 |
4 |
OE |
$10.29 |
$71,516 |
D/D |
6,950 |
29,492 |
|
- |
|
| Liang Hong |
SVP, Discovery Medicine |
• – – |
2020-03-19 |
4 |
AS |
$38.89 |
$157,811 |
D/D |
(4,000) |
138,166 |
|
8% |
|
| Baker Julian |
Director |
– • • |
2020-03-18 |
4 |
B |
$36.69 |
$1,322,977 |
I/I |
35,400 |
10,602,550 |
2.25 |
21% |
|
| Baker Julian |
Director |
– • • |
2020-03-17 |
4 |
B |
$38.99 |
$389,850 |
I/I |
10,000 |
10,570,083 |
2.25 |
13% |
|
| Baker Julian |
Director |
– • • |
2020-03-16 |
4 |
B |
$39.97 |
$4,180,977 |
I/I |
104,600 |
10,560,911 |
2.25 |
12% |
|
| Baker Julian |
Director |
– • • |
2020-02-26 |
4 |
B |
$57.82 |
$5,799,441 |
I/I |
100,000 |
10,464,977 |
2.25 |
-17% |
|
| Baker Julian |
Director |
– • • |
2020-02-25 |
4 |
B |
$57.22 |
$11,937,248 |
I/I |
206,126 |
10,373,248 |
2.25 |
-17% |
|
| Baker Julian |
Director |
– • • |
2020-02-24 |
4 |
B |
$55.45 |
$4,093,553 |
I/I |
71,123 |
10,184,170 |
2.25 |
-20% |
|
| Ehrlich Jason |
See Remarks |
• – – |
2019-12-23 |
4 |
OE |
$10.29 |
$11,062 |
D/D |
1,075 |
22,542 |
|
- |
|
| Ehrlich Jason |
See Remarks |
• – – |
2019-12-18 |
4 |
D |
$15.51 |
$132,347 |
D/D |
(8,533) |
21,467 |
|
- |
|
| Ehrlich Jason |
See Remarks |
• – – |
2019-12-18 |
4 |
OE |
$0.00 |
$0 |
D/D |
30,000 |
30,000 |
|
- |
|
| Baker Julian |
Director |
– • • |
2019-12-06 |
4 |
B |
$46.00 |
$87,499,958 |
I/I |
1,902,173 |
10,118,929 |
2.25 |
- |
|
| Liang Hong |
SVP, Discovery Medicine |
• – – |
2019-12-02 |
4 |
OE |
$1.04 |
$44,111 |
D/D |
42,166 |
142,166 |
|
- |
|
99 Records found
|
|
Page 4 of 4 |
|
|
0.07 (1.89%) 
